

PUBLICATION LIST NOVEMBER 2014– JOHNSEN HANS ERIK

PUBLICATION LIST– JOHNSEN HANS ERIK

A total of 242 original scientific papers, >50 over the last 5 years in international in peer reviewed journals (below). I have been investigator with no co authorship in international clinical trials (end section). Most important publications marked with *

Publications with peer review

2014

- 1) *Dybæk K; *Bøgsted M; Falgreen S, Bødker JS; Kjeldsen MK, Schmitz A; Bilgrau AE, Xu-Monette ZY; Li L; Bergkvist KS; Laursen MB; Rodrigo-Domingo M; Marques SC; Rasmussen SB; Nyegaard M; Gaihede M; Moeller MB; Samworth RJ; Shah RD; Johansen P; El-Galaly TC; Young KH and **Johnsen HE**. *Shared first authorship. A diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. Accepted for publication in Journal of Clinical Oncology, November 2014
- 2) Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol.* 2014 Nov;15(12):e538-48. doi:10.1016/S1470-2045(14)70442-5. Review.
- 3) Rasmussen SM, Bilgrau AE, Schmitz A, Falgreen S, Bergkvist KS, Tramm AM, Baech J, Jacobsen CL, Gaihede M, Kjeldsen MK, Bødker JS, Dybæk K, Bøgsted M, Johnsen HE. Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank. *Cytometry B Clin Cytom.* 2014 Oct 20. doi: 10.1002/cyto.b.21192. [Epub ahead of print] PubMed PMID: 25327569
- 4) Lanza F, Dallorso S, Milone G, Spedini P, Viganò C, Johnsen H. Quality assessment of autologous haematopoietic blood progenitor cell grafting. *Ann Hematol.* 2014 Oct 16. [Epub ahead of print] PubMed PMID: 25318761.
- 5) Rodrigo-Domingo M, Waagepetersen R, Bødker JS, Falgreen S, Kjeldsen MK, Johnsen HE, Dybæk K, Bøgsted M. Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. *Brief Bioinform.* 2014 Jul;15(4):519-33. PubMed PMID: 23603090; PubMed Central PMCID: PMC4103539.
- 6) Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, El-Galaly TC, Bøgsted M, Dybæk K, Johnsen HE; Myeloma Stem Cell Network MSCNET). Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. *Exp Hematol.* 2014 Jul 26. pii: S0301-472X(14)00598-0. doi: 10.1016/j.exphem.2014.07.263. [Epub ahead of print] Review. PubMed PMID: 25072621.
- 7) Falgreen S, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Dybæk K, Bøgsted M. Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. *BMC Bioinformatics.* 2014 Jun 5;15:168. doi: 10.1186/1471-2105-15-168. PubMed PMID: 24902483.
- 8) Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K. 2014. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti- myeloma activity of the BH3-mimetic ABT-737. *Oncotarget.* 2014 Apr 30. [Epub ahead of print] PubMed PMID: 25008202.
- 9) Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van deDonk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. 2014. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *Haematologica.* Feb;99(2):232-42.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

- 10) van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM. 2014. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. *Haematologica*. Mar 21. [Epub ahead of print]
- 11) Bergkvist KS, Nyegaard M, Bøgsted M, Schmitz A, Bødker JS, Rasmussen SM, Perez-Andres M, Falgreen S, Bilgrau AE, Kjeldsen MK, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Dybkær K, Johnsen HE. 2014. Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. *BMC Immunol*. 2014 Jan 31;15(1):3. [Epub ahead of print]
- 12) El-Galaly TC, Hutchings M, Mylam KJ, Brown PD, Bukh A, Johnsen HE, Kamper P, Loft A, Iyer V, Gormsen LC, Nielsen AL, Bøgsted M, d'Amore F. 2014. Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. *Leuk Lymphoma*. Feb 24. [Epub ahead of print].

2013

- 13) *Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE. 2013. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma, *PLoS One*, In press.
- 14) Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruutu T, Madrigal A, Johnsen HE. 2013. Individual Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society. Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Aug 27. [Epub ahead of print]
- 15) *Johnsen HE, Bergkvist KS, Schmitz A, Kjeldsen MK, Hansen SM, Gaihede M, Nørgaard MA, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Bødker JS, Bøgsted M, Dybkær K; for the Myeloma Stem Cell Network (Mscnet). 2013. Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. *Leuk Lymphoma*. Nov 1. [Epub ahead of print]
- 16) Dabrowska MJ, Ejegod D, Lassen LB, Johnsen HE, Wabl M, Pedersen FS, Dybkær K. 2013. Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes. *Leuk Res*. 37(10):1383-90.
- 17) Kloster MB, Bilgrau AE, Rodrigo-Domingo M, Bergkvist KS, Schmitz A, Sønderkær M, Bødker JS, Falgreen S, Nyegaard M, Johnsen HE, Nielsen KL, Dybkaer K, Bøgsted M. 2012. A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells. *BMC Genomics*. 5;13:596.
- 18) Bødker JS, Gyruup C, Johansen P, Schmitz A, Madsen J, Johnsen HE, Bøgsted M, Dybkær K, Nyegaard M. 2013. Performance Comparison of Affymetrix SNP6.0 and Cytogenetic 2.7M Whole-Genome Microarrays in Complex Cancer Samples. *Cytogenet Genome Res*. 139(2):80-7.

2012

- 19) Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D. 2012. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. *Bone Marrow Transplant*. [Epub ahead of print]
- 20) El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, Specht L, Loft A, Iyer V, Hjorthaug K, Nielsen AL, Christiansen I, Madsen C, Johnsen HE, Hutchings M. 2012. Routine bone marrow biopsy has little or no therapeutic

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. *J Clin Oncol* 20;30(36):4508-14.

21) *Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhler S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. 2012. Cancer stem cell definitions and terminology: the devil is in the details. *Nat Rev Cancer*. (11):767-75.

22) Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ. 2012. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. *Leuk Res*. 36(5):548-53.

23) *Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodgkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE; European Myeloma Network. 2012. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. *Haematologica*. 97(8):1272-7.

24) *Hoffmann MH, Klausen TW, Boegsted M, Larsen SF, Schmitz A, Leino EB, Schmiegelow K, Hasle H, Bergmann OJ, Sorensen S, Nyegaard M, Dybkaer K, Johnsen HE. 2012. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. *Cytometry B Clin Cytom*. 82(3):123-31.

25) Johnsen HE, Haioun C, Lugtenburg PJ, Salar A, Jaeger U, Pettengell R, Rossi FG, Verhoef G, Schwenkglenks M, Bendall K, Duehrsen U. 2012. Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. *Leuk Lymphoma*. [Epub ahead of print]

26) Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim CS, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R. 2012. MyelomaA Genetics International Consortium. *Leuk Lymphoma*. 53(5):796-800.

27) Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orłowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. 2012. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*. 26(1):149-57.

2011

28) Gottlieb H, Klausen TW, Boegsted M, Olsen BS, Lausten GS, Kastrup J, Johansen JS, Nyegaard M, Dybkaer K and Johnsen HE. (2011) A Clinical Study of Circulating Cellular and Humoral Biomarkers Involved in Bone Regeneration Following Traumatic Lesions. *Stem Cell Res Ther* 1:108.

29) Leino E, Nielsen KR, John B, Rudi S, Karen D, et al. (2011) Quantitation of Megakaryocytic Progenitors in Apheresis Products by Flow Cytometry and Real Time PCR. *J Stem Cell Res Ther* S3:001.

30) El-Galaly T, Mylam KJ, Brown P, Specht L, Christiansen I, Munksgaard L, Johnsen HE, Loft A, Bukh A, Iyer V, Lerberg Nielsen A, Hutchings M. 2011. PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. *Haematologica*. [Epub ahead of print]

31) R Pettengell, HE Johnsen, P Lugtenburg, A Salar, U Duehrsen U, FG Rossi, M Schwenkglenks, K Bendall, Z Szabo, U Jaeger. 2012. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. *Support Care Cancer*. 20(3):647-52. [Epub 2011 Nov 20. PubMed PMID: 22101611; PubMed Central PMCID: PMC3271211. Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

hospitalizations among patients with diffuse large B-cell lymphoma. *Support Care Cancer*. 2013 Feb;21(2):653. doi: 10.1007/s00520-012-1678-2].

32) *Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hájek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. 2011. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). *Blood*. 118(17):4519-29. Epub 2011 Aug. 12. Review.

33) *Kjeldsen MK, Perez-Andres M, Schmitz A, Johansen P, Boegsted M, Nyegaard M, Gaihede M, Bukh A, Johnsen HE, Orfao A, Dybkaer K. 2011. Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue. *Am J Clin Pathol*. 136(6):960-9.

34) Nielsen KR, Steffensen R, Boegsted M, Baech J, Lundbye-Christensen S, Hetland ML, Krintel SB, Johnsen HE, Nyegaard M, Johansen JS. 2011. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. *Arthritis Res Ther*. 13(3):R109.

35) *Boegsted M, Holst JM, Fogd K, Falgreen S, Sørensen S, Schmitz A, Bukh A, Johnsen HE, Nyegaard M, Dybkaer K. 2011. Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines. *PLoS One*. 6(4):e19322.

36) Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International Myeloma Working Group. 2011. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood*. 117(23):6063-73.

37) Haioun C, Salar A, Pettengell R, Johnsen HE, Duehrsen U, Rossi FG, Verhoef G, Schwenkglenks M, Jaeger U, Hamilton L, Pujol B, Lugtenburg PJ. 2011. Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. *Leuk Lymphoma*. 52(5):796-803.

38) Johnsen HE, Pilgaard L, Højfeldt AD, Andersson TL, Schmitz A, Gade KH, Fogd K, Nyegaard M, Bøgsted M, Dybkær K. 2011. [The haematological biobank - an infrastructure for quality assurance, development and research.]. *Ugeskr Laeger*. 173(21):1489-1493.

39) El-Galaly T, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M, Johnsen HE, Bukh A. 2011. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. *Leuk Lymphoma*. 52(4):597-603.

40) Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de Las HN, Mateos MV, et al. 2011. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. *Leukemia*. 25(4):697-706.

41) Johnsen HE, Geisler C, Juvonen E, Remes K, Juliusson G, Hörnsten P, Kvaloy S, Kvalheim G, Jürgensen GW, Pedersen LM, Bergmann OJ, Schmitz A, Boegsted M. 2011. Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment. *Bone Marrow Transplant*. 46(1):44-51.

42) van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A. 2011. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. *Cancer Treat Rev*. 37(4):266-83.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

2010

- 43) Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, et al. 2010. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. *Scand J Immunol* 72(6):540-7.
- 44) Hojfeldt AD, Johnsen HE, Bogsted M, Schmitz A, Fogd K, Pilgaard L, et al. 2010. [Use of translational database at clinical department]. *Ugeskr Laeger* 172(28):2062-4.
- 45) Johnsen HE, Klausen TW, Boegsted M, Lenhoff S, Gimsing P, Christiansen I, et al. 2010. Improved survival for multiple myeloma in Denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behaviour on survival in more than 1200 patients in trials of the Nordic myeloma study group. *Clin Lymphoma Myeloma Leuk* 10(4):290-6.
- 46) Johnsen HE, Korup J, Lundby L, Dybkaer K, Bukh A 2010. [The clinical research unit]. *Ugeskr Laeger* 172(18):1380-3.
- 47) Juul T, Malolepszy A, Dybkaer K, Kidmose R, Rasmussen JT, Andersen GR, et al. 2010. The in vivo toxicity of hydroxyurea depends on its direct target catalase. *J Biol Chem* 285(28):21411-5.
- 48) Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, et al. 2010. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. *Cytometry B Clin Cytom* 78 Suppl 1:S47-S60.
- 49) Urup T, Madsen G, Hallager S, Schmitz A, Fogd K, Bogsted M, et al. 2010. [Cancer stem cells in the haematopoietic system]. *Ugeskr Laeger* 172(38):2597-600.
- 50) Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. 2010. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. *Leuk Lymphoma*. 51(11):2006-11.
- 51) *Johnsen HE, Bøgsted M, Klausen TW, Gimsing P, Schmitz A, Kjaersgaard E, Damgaard T, Voss P, Knudsen LM, Mylin AK, Nielsen JL, Björkstrand B, Gruber A, Lenhoff S, Remes K, Dahl IM, Fogd K, Dybkaer K; Nordic Myeloma Study (NMSG); Myeloma Stem Cell Network (MSCNET). 2010. Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. *Cytometry B Clin Cytom*. 78(5):338-47.
- 52) *Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup GB, Lodahl M, Johnsen HE, Kuehl M. 2010. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. *Haematologica*. 95(10):1730-7.
- 53) Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A, Perez-Andres M; Myeloma Stem Cell Network. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. *Haematologica*. 2010 Jun;95(6):1016-20.
- 54) Johnsen HE, Hoffmann MH, Klausen TW, Davidsen UH, Bergmann OJ, Boegsted M, Nyegaard M, Bukh A and Dybkaer K. Health Technology Assessment of Multiplex Reverse Transcriptase- Polymerase Chain Reaction Screening for Translocations at Diagnosis in Acute Myeloid Leukaemia. *European Haematology* 2010. 4s: 39-42
- 55) Fogd K, Hansen SM, Madsen LH, Kjeldsen MK and Johnsen HE. The Cancer Stem Cell Concept in Multiple Myeloma - From Phenomenology to Characterisation. 2010. *European Haematology*. 4, s. 94-96

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

2009

- 56) Bjorkstrand B, Klausen TW, Remes K, Gruber A, Knudsen LM, Bergmann OJ, et al. Double versus single high-dose melphalan 200 mg/m² and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area. *Hematology Reviews* 2009;1(e2):9-13. PagePress.
- 57) Dabrowska MJ, Dybkaer K, Johnsen HE, Wang B, Wabl M, Pedersen FS. Loss of microRNA-targets in the 3'-untranslated region as a mechanism of retroviral insertional activation of Growth Factor Independence 1. *J Virol* 2009 May 27.
- 58) Johnsen HE, Kjeldsen MK, Urup T, Fogd K, Pilgaard L, Boegsted M, et al. Cancer stem cells and the cellular hierarchy in haematological malignancies. *Eur J Cancer* 2009 Sep;45 Suppl 1:194-201.
- 59) Johnsen HE, Knudsen LM, Mylin AK, Gimsing P, Gregersen H, Abildgaard N, Andersen NF, Plesner T, Vangsted A, Mourits-Andersen T. Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial. *Hematology Reviews* 2009; Vol 1, No 2. PagePress.

2008

- 60) Haack-Sorensen M, Friis T, Bindslev L, Mortensen S, Johnsen HE, Kastrup J. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. *Scand J Clin Lab Invest* 2008;68(3):192-203.
- 61) Khan AE, Gallo V, Linseisen J, Kaaks R, Rohrmann S, Raaschou-Nielsen O, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. *Haematologica* 2008 Jun;93(6):842-50.
- 62) Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. *Cancer* 2008 Jan 1;112(1):129-35.
- 63) Petruskevicius I, Bukh A, Mertz H, Johnsen HE. [Complete remission after Rituximab treatment in refractory hairy cell leukemia]. *Ugeskr Laeger* 2008 Jun 23;170(26-32):2350.
- 64) Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. *Haematologica* 2008 Mar;93(3):431-8.
- 65) Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. *Haematologica* 2008 Mar;93(3):405-12.

2007

- 66) Ripa RS, Wang Y, Goetze JP, Jorgensen E, Johnsen HE, Tagil K, et al. Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease--indicators of myocardial ischemic burden? *Int J Cardiol* 2007 Aug 21;120(2):181-7.
- 67) Rohrmann S, Becker N, Linseisen J, Nieters A, Rudiger T, Raaschou-Nielsen O, et al. Fruit and vegetable consumption and lymphoma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control* 2007 Jun;18(5):537-49.
- 68) Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. *Cancer Immunol Immunother* 2007 Sep;56(9):1485-99.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

69) Svane IM, Nikolajsen K, Johnsen HE. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. *Scand J Immunol* 2007 Oct;66(4):465-75.

2006

70) Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. *Clin Exp Immunol* 2006 Apr;144(1):76-84.

71) Chabanova E, Johnsen HE, Knudsen LM, Larsen L, Logager V, Yingru S, et al. Magnetic resonance investigation of bone marrow following priming and stem cell mobilization. *J Magn Reson Imaging* 2006 Dec;24(6):1364-70.

72) Jorgensen E, Ripa RS, Helqvist S, Wang Y, Johnsen HE, Grande P, et al. In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor Preliminary intracoronary ultrasound results from a double-blind randomized placebo-controlled study of patients treated with percutaneous coronary intervention for ST-elevation myocardial infarction (STEMMI Trial). *Int J Cardiol* 2006 Jul 28;111(1):174-7.

73) Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. *Br J Haematol* 2006 May;133(4):389-96.

74) Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisloff F, et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. *Haematologica* 2006 Sep;91(9):1228-33.

75) Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Norgaard PH, Lenhoff S, et al. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. *Eur J Haematol* 2006 Nov;77(5):416-24.

76) Norgaard M, Poulsen AH, Pedersen L, Gregersen H, Friis S, Ewertz M, et al. Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study. *Br J Cancer* 2006 May 8;94(9):1339-41.

77) Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. *Eur Heart J* 2006 Aug;27(15):1785-92.

78) Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. *Circulation* 2006 Apr 25;113(16):1983-92.

79) Roer O, Hammerstrom J, Lenhoff S, Mylin AK, Knudsen LM, Rasmussen T, et al. Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients. *Cytotherapy* 2006;8(1):79-88.

80) Schroder H, Kjeldstad M, Boesen AM, Nielsen OJ, Schmidt KG, Johnsen HE, et al. [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?]. *Ugeskr Laeger* 2006 Jun 26;168(26-32):2554-8.

81) Schroder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE, et al. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication. *Dan Med Bull* 2006 Feb;53(1):76-9.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

82) Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, Haack-Sorensen M, et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. *Heart* 2006 Jun;92(6):768-74.

2005

83) Bergmann OJ, Johansen JS, Klausen TW, Mylin AK, Kristensen JS, Kjeldsen E, et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. *Clin Cancer Res* 2005 Dec 15;11(24 Pt 1):8644-52.

84) Bukh A, D'Amore FA, Gimsing P, Hasselbalch HC, Johnsen HE, Kerndrup GB, et al. [Designer drugs and their rational use in clinical hematology]. *Ugeskr Laeger* 2005 May 16;167(20):2180-3.

85) Chang ET, Hjalgrim H, Smedby KE, Akerman M, Tani E, Johnsen HE, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. *J Natl Cancer Inst* 2005 Feb 2;97(3):210-8.

86) Dufva IH, Karle H, Brondum-Nielsen K, Andersen MK, Madsen HO, Johnsen HE. Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy. *Leukemia* 2005 Apr;19(4):671-3.

87) Hudlebusch HR, Theilgaard-Monch K, Lodahl M, Johnsen HE, Rasmussen T. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. *Br J Haematol* 2005 Sep;130(5):700-8.

88) Hutchings HM, Wirenfeldt KT, Hasle H, Schmiegelow K, Brondum-Nielsen K, Johnsen HE. Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance. *Haematologica* 2005 Jul;90(7):984-6.

89) Leino EB, Hoffmann MH, Kjaersgaard E, Nielsen JD, Bergmann OJ, Klausen TW, et al. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. *Br J Haematol* 2005 Feb;128(4):526-32.

90) Pedersen AE, Thorn M, Gad M, Walter MR, Johnsen HE, Gaarsdal E, et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. *Scand J Immunol* 2005 Feb;61(2):147-56.

91) Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. *Ann Hematol* 2005 Aug;84(8):510-6.

92) Pedersen LM, Johnsen HE. Microalbuminuria is associated with impaired glomerular permselectivity in lymphoma patients. *Scand J Clin Lab Invest* 2005;65(6):477-84.

93) Pedersen LM, Jurgensen GW, Johnsen HE. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. *Br J Haematol* 2005 Mar;128(6):813-9.

94) Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. *Blood* 2005 Jan 1;105(1):317-23.

95) Wang Y, Tagil K, Ripa RS, Nilsson JC, Carstensen S, Jorgensen E, et al. Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. *Int J Cardiol* 2005 Apr 28;100(3):477-83.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

2004

- 96) Do TH, Johnsen HE, Kjaersgaard E, Taaning E, Svane IM. Impaired circulating myeloid DCs from myeloma patients. *Cytotherapy* 2004;6(3):196-203.
- 97) Hudlebusch HR, Lodahl M, Johnsen HE, Rasmussen T. Expression of HOXA genes in patients with multiple myeloma. *Leuk Lymphoma* 2004 Jun;45(6):1215-7.
- 98) Leinoe EB, Hoffmann MH, Kjaersgaard E, Johnsen HE. Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia. *Br J Haematol* 2004 Oct;127(1):76-84.
- 99) Poulsen TS, Johnsen HE. BAC end sequencing. *Methods Mol Biol* 2004;255:157-61.
- 100) Rasmussen T, Lodahl M, Hancke S, Johnsen HE. In multiple myeloma clonotypic. *Leuk Lymphoma* 2004 Jul;45(7):1413-7.
- 101) Rasmussen T, Knudsen LM, Huynh TK, Johnsen HE. Molecular and clinical follow-up after treatment of multiple myeloma. *Acta Haematol* 2004;112(1-2):105-10.
- 102) Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. *Cancer Immunol Immunother* 2004 Jul;53(7):633-41.

2003

- 103) Baech J, Roer O, Johnsen HE. Individual quality assessment of autografting by probability evaluation: a model estimated by analysis of graft-related end points in 204 patients with malignancies. *Bone Marrow Transplant* 2003 Mar;31(6):453-8.
- 104) Bjorkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi TT, Johnsen HE. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study. *Eur J Haematol* 2003 Jun;70(6):379-83.
- 105) Kassem M, Kastrup J, Olsen G, Johnsen HE. [Mesenchymal stem cell therapy--the key to regenerative medicine?]. *Ugeskr Laeger* 2003 Dec 8;165(50):4852-5.
- 106) Rasmussen T, Theilgaard-Monch K, Hudlebusch HR, Lodahl M, Johnsen HE, Dahl IM. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. *Br J Haematol* 2003 Oct;123(2):253-62.
- 107) Rasmussen T, Knudsen LM, Dahl IM, Johnsen HE. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. *Leuk Lymphoma* 2003 Oct;44(10):1761-6.
- 108) Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. FGFR3 dysregulation and clinical outcome in myeloma. *Br J Haematol* 2003 Jan;120(1):166.
- 109) Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotypic vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. *Blood* 2003 Jun 1;101(11):4607-10.
- 110) Schetelig J, Fetscher S, Reichle A, Berdel WE, Beguin Y, Brunet S, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. *Haematologica* 2003 Nov;88(11):1272-8.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

111) Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. *J Clin Oncol* 2003 Nov 1;21(21):3918-27.

112) Svane IM, Soot ML, Buus S, Johnsen HE. Clinical application of dendritic cells in cancer vaccination therapy. *APMIS* 2003 Jul;111(7-8):818-34.

113) Yongzhong W, Johnsen HE, Jorgensen E, Kastrup J. The clinical impact of vascular growth factors and endothelial progenitor cells in the acute coronary syndrome. *Scand Cardiovasc J* 2003;37(1):18-22.

2002

114) Gisselo CG, Roer O, Hoffmann MH, Hansen MB, Taaning E, Johnsen HE. Assessing agreement between CD34 enumeration by flow cytometry and volumetric analysis. *Bone Marrow Transplant* 2002 Apr;29(8):699-703.

115) Johnsen HE, Lanza F. Clinical validation--the final step in translational medicine! From CD34 enumeration to probability estimation of autograft quality. *J Biol Regul Homeost Agents* 2002 Oct;16(4):270-1.

116) Johnsen HE, Lanza F. Quality assessment of autologous hematopoietic blood progenitor and stem cell grafting: a prospective registration study. *J Biol Regul Homeost Agents* 2002 Oct;16(4):272-88.

117) Poulsen TS, Silahatoglu AN, Gisselo CG, Tommerup N, Johnsen HE. Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes. *Leukemia* 2002 Oct;16(10):2148-55.

118) Rasmussen T, Bjorkstrand B, Andersen H, Gaarsdal E, Johnsen HE. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. *Exp Hematol* 2002 Jan;30(1):82-8.

119) Rasmussen T, Jensen L, Johnsen HE. The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. *Leuk Lymphoma* 2002 May;43(5):1075-7.

120) Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. *Br J Haematol* 2002 Jun;117(3):626-8.

121) Svane IM, Nikolajsen K, Hansen SW, Kamby C, Nielsen DL, Johnsen HE. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method. *Bone Marrow Transplant* 2002 Apr;29(8):659-66.

122) Svane IM, Homburg KM, Kamby C, Nielsen DL, Roer O, Sliffsgaard D, et al. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. *Acta Oncol* 2002;41(7-8):675-83.

2001

123) Johnsen HE. Clinical practice and future needs in recombinant human granulocyte colony-stimulating factor treatment: a review of randomized trials in clinical haemato-oncology. *J Int Med Res* 2001 Mar;29(2):87-99.

124) Knudsen LM, Nikolajsen K, Gaarsdal E, Johnsen HE. Kinetic studies during peripheral blood stem cell collection show CD34+ cell recruitment intra-apheresis. *J Clin Apher* 2001;16(3):114-9.

125) Knudsen LM, Rasmussen T, Nikolajsen K, Johnsen HE. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. *Eur J Haematol* 2001 Nov;67(5-6):289-95.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

126) Poulsen TS, Silahtaroglu AN, Gisselo CG, Gaarsdal E, Rasmussen T, Tommerup N, et al. Detection of illegitimate rearrangement within the immunoglobulin locus on 14q32.3 in B-cell malignancies using end-sequenced probes. *Genes Chromosomes Cancer* 2001 Nov;32(3):265-74.

127) Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. *Eur J Haematol* 2001 Nov;67(5-6):296-301.

128) Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. *Bone Marrow Transplant* 2001 Mar;27(5):463-70.

2000

129) Baech J, Johnsen HE. Technical aspects and clinical impact of hematopoietic progenitor subset quantification. *Stem Cells* 2000;18(2):76-86.

130) Johnsen HE. [Myelomatosis--toward a breakthrough? The Danish Society of Hematology]. *Ugeskr Laeger* 2000 Mar 20;162(12):1712.

131) Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. *Nordic Myeloma Study Group. Blood* 2000 Jan 1;95(1):7-11.

132) Meldgaard KL, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. *Bone Marrow Transplant* 2000 Oct;26(7):717-22.

133) Rasmussen T, Jensen L, Johnsen HE. The clonal hierachy in multiple myeloma. *Acta Oncol* 2000;39(7):765-70.

134) Rasmussen T, Jensen L, Johnsen HE. Levels of circulating CD19+ cells in patients with multiple myeloma. *Blood* 2000 Jun 15;95(12):4020-1.

135) Rasmussen T, Jensen L, Honore L, Johnsen HE. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. *Blood* 2000 Dec 15;96(13):4357-9.

136) Rasmussen T, Poulsen TS, Honore L, Johnsen HE. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay. *Exp Hematol* 2000 Sep;28(9):1039-45.

137) Rasmussen T, Dahl IM, Jensen L, Johnsen HE. CD68+/CD83+/CD1a- dendritic cell subsets from patients with multiple myeloma are not infected with human herpesvirus 8. *Med Oncol* 2000 Aug;17(3):189-94.

138) Richel DJ, Johnsen HE, Canon J, Guillaume T, Schaafsma MR, Schenkeveld C, et al. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. *Bone Marrow Transplant* 2000 Feb;25(3):243-9.

139) Schiodt I, Jensen CH, Kjaersgaard E, Gaarsdal E, Nikolajsen K, Johnsen HE. Flow cytometric detection of growth factor receptors in autografts and analysis of growth factor concentrations in autologous stem cell transplantation: possible significance for platelet recovery. *Bone Marrow Transplant* 2000 Sep;26(5):525-31.

1999

140) de Wynter EA, Ryder D, Lanza F, Nadali G, Johnsen H, ning-Kendall P, et al. Multicentre European study comparing selection techniques for the isolation of CD34+ cells. *Bone Marrow Transplant* 1999 Jun;23(11):1191-6.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

- 141) Johnsen HE, Baech J, Nikolajsen K. Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. Nordic Stem Cell Laboratory Group. *J Hematother* 1999 Feb;8(1):15-28.
- 142) Johnsen HE, Hutchings M, Taaning E, Rasmussen T, Knudsen LM, Hansen SW, et al. Selective loss of progenitor subsets following clinical CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation. *Bone Marrow Transplant* 1999 Dec;24(12):1329-36.
- 143) Johnsen HE. Does recombinant human granulocyte colony-stimulating factor really prime marrow stem cells in mice and humans? *Blood* 1999 Jun 15;93(12):4446-9.
- 144) Johnsen HE, Davidsen UH. [Morbidity from birth to death or a sick idea?]. *Ugeskr Laeger* 1999 Mar 15;161(11):1622.
- 145) Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. *Med Oncol* 1999 Dec;16(4):245-54.
- 146) Meldgaard KL, Jensen L, Jarlbaek L, Hansen PG, Hansen SW, Drivsholm L, et al. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. *Haematologica* 1999 Jun;84(6):517-24.
- 147) Rasmussen T, Jensen L, Honore L, Andersen H, Johnsen HE. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. *Br J Haematol* 1999 Dec;107(4):818-24.
- 148) Rasmussen T, Kastrup J, Knudsen LM, Johnsen HE. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. *Br J Haematol* 1999 Apr;105(1):265-7.
- 149) Schiodt I, Knudsen L, Jensen L, Nikolajsen E, Gaarsdal E, Johnsen H. Response to the comment on 'Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF' by JM miclea. *Bone Marrow Transplant* 1999 Aug;24(4):442-3.
- 150) Serke S, Huhn D, Johnsen HE, Herrmann R. Detrimental effects of prechemotherapy filgrastim. *J Clin Oncol* 1999 Mar;17(3):1088-90.
- 151) Serke S, Johnsen H, Huhn D, Kvalheim G. European Survey of the Flow Cytometric Determination of CD34-Expressing Cells. *Cytotherapy* 1999;1(4):343-7.
- 152) Verfaillie CM, Ploemacher R, Persio JD, Sutherland D, Serke S, Johnsen H, et al. ISHAGE Scientific Committee Report Assays to determine hematopoietic stem cell content in blood or marrow grafts. *Cytotherapy* 1999;1(1):41-9.
- 1998**
- 153) Baggers J, Johnsen HE. [Prognosis of hematological patients with relapse following high-dose chemotherapy and autologous stem cell transplantation]. *Ugeskr Laeger* 1998 Sep 14;160(38):5505-8.
- 154) Gratama JW, Orfao A, Barnett D, Brando B, Huber A, Janossy G, et al. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. *Cytometry* 1998 Jun 15;34(3):128-42.
- 155) Hansen PB, Penkowa M, Johnsen HE. Hematopoietic growth factors for the treatment of myelodysplastic syndromes. *Leuk Lymphoma* 1998 Feb;28(5-6):491-500.
- 156) Hutchings M, Moriwaki K, Dilloo D, Hoffmann T, Kimbrough S, Johnsen HE, et al. Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. *J Hematother* 1998 Jun;7(3):217-24.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

- 157) Johnsen HE. The real CD34+ events: simplicity or complexity? *Exp Hematol* 1998 Jul;26(7):550-1.
- 158) Johnsen HE, Rasmussen T, Knudsen LM. CD34+ subset and tumor cell quantitation by flow cytometry--step toward quality assessment of autografts in B cell malignancies. *Vox Sang* 1998;74 Suppl 2:477-82.
- 159) Knudsen LM, Hansen SW, Daugard G, Jarlbaek L, Agerbaek M, Jensen L, et al. Comparison of rhG--CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours. *Eur J Haematol* 1998 Oct;61(4):229-34.
- 160) Knudsen LM, Gaarsdal E, Jensen L, Nikolaisen K, Johnsen HE. Evaluation of mobilized CD34+ cell counts to guide timing and yield of large-scale collection by leukapheresis. *J Hematother* 1998 Feb;7(1):45-52.
- 161) Marti G, Johnsen H, Sutherland R, Serke S. A convergence of methods for a worldwide standard for CD34+ cell enumeration. *J Hematother* 1998 Apr;7(2):105-9.
- 162) Rasmussen T, Honore L, Johnsen HE. Identification and characterisation of malignant cells using RT-PCR on single flow-sorted cells. *Med Oncol* 1998 Jul;15(2):96-102.
- 163) Schiodt I, Knudsen LM, Jensen L, Nikolajsen K, Gaarsdal E, Johnsen HE. Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF. *Bone Marrow Transplant* 1998 Jun;21(11):1167-9.
- 164) Schiodt I, Bergmann OJ, Johnsen HE, Hansen NE. Early infections after autologous transplantation for haematological malignancies. *Med Oncol* 1998 Jul;15(2):103-8.
- 1997**
- 165) Hansen NE, Hutchings M, Johnsen HE, Knudsen LM, Rasmussen T. [The human hematopoietic stem cell biology and clinical use]. *Ugeskr Laeger* 1997 Jun 30;159(27):4253-6.
- 166) Helleberg C, Knudsen H, Hansen PB, Nikolajsen K, Kjaersgaard E, Ralfkiaer E, et al. CD34+ megakaryoblastic leukaemic cells are CD38-, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? *Leukemia* 1997 Jun;11(6):830-4.
- 167) Johnsen HE. Toward a worldwide standard for CD34+ enumeration? *J Hematother* 1997 Apr;6(2):83-9.
- 168) Serke S, Arseniev L, Watts M, Fritsch G, Ingles-Esteve J, Johnsen HE, et al. Imprecision of counting CFU-GM colonies and CD34-expressing cells. *Bone Marrow Transplant* 1997 Jul;20(1):57-61.
- 1996**
- 169) Johnsen HE, Knudsen LM. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). *J Hematother* 1996 Jun;5(3):237-45.
- 170) Johnsen HE, Bjorkstrand B, Carlson K, Gruber A, Blystad A, Fast A, et al. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. *Leuk Lymphoma* 1996 Dec;24(1-2):81-91.
- 171) Johnsen HE, Morling N. [Single cell sorting of human hematopoietic stem cells--why, how and with what consequences?]. *Ugeskr Laeger* 1996 Mar 18;158(12):1687-9.
- 172) Knudsen LM, Gaarsdal E, Jensen L, Nielsen KJ, Nikolaisen K, Johnsen HE. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. *J Hematother* 1996 Aug;5(4):399-406.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

173) Serke S, Watts M, Knudsen LM, Kreissig C, Schneider U, Schwella N, et al. In-vitro clonogenicity of mobilized peripheral blood CD34-expressing cells: inverse correlation to both relative and absolute numbers of CD34-expressing cells. *Br J Haematol* 1996 Nov;95(2):234-40.

1995

174) Hansen B, Jensen KE, Larsen VA, Johnsen HE, Nielsen H, Karle H, et al. [Short-term stimulation with myeloid growth factors expands bone marrow hematopoiesis. A magnetic resonance spectroscopic study]. *Ugeskr Laeger* 1995 Nov 6;157(45):6265-9.

175) Hansen PB, Johnsen HE, Jensen L, Gaardsdal E, Simonsen K, Ralfkiaer E. Priming and treatment with molgramostim (rhGM-CSF) in adult high-risk acute myeloid leukemia during induction chemotherapy: a prospective, randomized pilot study. *Eur J Haematol* 1995 May;54(5):296-303.

176) Hansen PB, Johnsen HE, Ralfkiaer E, Jensen L, Gaardsdal E, Hansen NE. Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas. *Leuk Lymphoma* 1995 Nov;19(5-6):453-60.

177) Hansen PB, Knudsen H, Gaardsdal E, Jensen L, Ralfkiaer E, Johnsen HE. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability. *Bone Marrow Transplant* 1995 Sep;16(3):373-9.

178) Hansen PB, Johnsen HE, Lund JO, Hansen MS, Hansen NE. Unexpected hepatotoxicity after priming and treatment with molgramostim (rhGM-CSF) in acute myeloid leukemia during induction chemotherapy. *Am J Hematol* 1995 Jan;48(1):48-51.

179) Hansen PB, Knudsen LM, Johnsen HE, Hansen NE. Stimulation tests for the bone marrow neutrophil pool in malignancies. *Leuk Lymphoma* 1995 Jan;16(3-4):237-46.

180) Helleberg C, Taaning EB, Johnsen HE. [Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment]. *Ugeskr Laeger* 1995 Sep 11;157(37):5082-6.

181) Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. *J Hematother* 1995 Feb;4(1):21-8.

182) Johnsen HE, Karle H. [Molecular biology in practice. Chronic myeloid leukemia]. *Ugeskr Laeger* 1995 Jun 19;157(25):3608-10.

183) Knudsen LM, Petersen TL, Jensen TS, Johnsen HE. [Hematologic regeneration after high dose chemotherapy. Use of peripheral blood stem cells]. *Ugeskr Laeger* 1995 Sep 4;157(36):4927-31.

184) Knudsen LM, Johnsen HE, Gaardsdal E, Jensen L. Spinal versus general anaesthesia for bone marrow harvesting. *Bone Marrow Transplant* 1995 Mar;15(3):486-7.

185) nneskiold-Samsoe B, Dickmeiss E, Georgsen J, Heilmann C, Heslet L, Hovendal C, et al. [Recommendations for use of leukocyte-depleted blood components]. *Ugeskr Laeger* 1995 Mar 20;157(12):1685-6.

1994

186) Jensen KE, Hansen PB, Larsen VA, Johnsen HE, Nielsen H, Karle H, et al. Short-term myeloid growth factor mediated expansion of bone marrow haemopoiesis studied by localized magnetic resonance proton spectroscopy. *Br J Haematol* 1994 Nov;88(3):465-71.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

187) Johnsen HE, Jensen L, Gaarsdal E, Hansen PB, Ersboll J, Hansen NE. Priming with recombinant human hematopoietic cytokines before bone marrow harvest expands in vivo and enhances ex vivo recovery of myeloid progenitors in short-term liquid cultures. *Exp Hematol* 1994 Jan;22(1):80-6.

188) Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. *Am J Clin Pathol* 1994 Dec;102(6):835-41.

1993

189) Hansen PB, Kjaersgaard E, Johnsen HE, Gram J, Pedersen M, Nikolajsen K, et al. Different membrane expression of CD11b and CD14 on blood neutrophils following in vivo administration of myeloid growth factors. *Br J Haematol* 1993 Sep;85(1):50-6.

190) Hansen PB, Johnsen HE, Hippe E. Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor. *Eur J Haematol* 1993 Mar;50(3):183-4.

191) Hansen PB, Johnsen HE, Hippe E, Hellstrom-Lindberg E, Ralfkiaer E. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. *Am J Hematol* 1993 Dec;44(4):229-36.

192) Hansen PB, Johnsen HE, Ralfkiaer E, Hansen NE. Blood neutrophil increment after a single injection of rhG-CSF or rhGM-CSF correlates with marrow cellularity and may predict the grade of neutropenia after chemotherapy. *Br J Haematol* 1993 Aug;84(4):581-5.

193) Hansen PB, Johnsen HE, Hippe E. Hypereosinophilic syndrome treated with alpha-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity. *Am J Hematol* 1993 May;43(1):66-8.

194) Johnsen HE. Predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. *N Engl J Med* 1993 May 20;328(20):1497-8.

195) Johnsen HE. [Autologous bone marrow transplantation]. *Ugeskr Laeger* 1993 Apr 5;155(14):1062-3.

196) Johnsen HE, Gaarsdal E, Jensen L, Philip P, Hansen NE. Short-term liquid marrow cultures are supported by a mixture of haematopoietic cytokines but do not purge for acute myeloid or lymphoid leukemic marrow cells. *Leukemia* 1993 Sep;7(9):1402-8.

1992

197) Hansen B, Hippe E, Jacobsen GK, Johnsen HE. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency]. *Ugeskr Laeger* 1992 Jun 8;154(24):1697-702.

198) Johnsen HE, Mickelson E, Beatty PG, Hansen JA. Donor alloreactivity may predict acute graft-versus-host disease in patients receiving marrow transplants from HLA identical siblings. *Bone Marrow Transplant* 1992 Feb;9(2):91-6.

199) Johnsen HE, Bostrom L, Moller J, Jorgensen JA, Jensen L, Ringden O. A study of donor alloreactivity, which may predict acute graft-versus-host disease in HLA identical bone marrow transplantations for early leukaemia. *Scand J Immunol* 1992 Mar;35(3):353-60.

200) Johnsen HE, Beatty PG, Michelson E, Hansen JA, Thomas ED. Donor alloreactivity may predict acute graft-versus-host disease in HLA-matched bone marrow transplantation for leukemia in early remission. *Eur J Haematol* 1992 May;48(5):249-53.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

201) Johnsen HE, Hansen PB, Plesner T, Jensen L, Gaarsdal E, Andersen H, et al. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. *Bone Marrow Transplant* 1992 Sep;10(3):229-34.

202) Lindhart PT, Pedersen M, Myhre J, Milman N, Johnsen H. Bronchoalveolar lavage is a safe and informative procedure in haematologic patients with nonresolving pneumonia. *Eur J Haematol* 1992 Nov;49(5):280-1.

1991

203) Johnsen HE, Kjaer M, Skinhoj P, Jacobsen N. [Acquired severe aplastic anemia. Therapeutic effect and prognosis after allogeneic bone marrow transplantation]. *Ugeskr Laeger* 1991 Jan 7;153(2):101-4.

204) Johnsen HE, Birgens H, Hansen NE. [Autologous bone marrow transplantation in malignant hematologic diseases]. *Ugeskr Laeger* 1991 Jun 17;153(25):1790-3.

1990-1981

205) Hansen B, Johnsen HE. [Myeloid hemopoietic growth factors. Therapeutic possibilities and clinical experiences]. *Ugeskr Laeger* 1990 Oct 29;152(44):3232-7.

206) Johnsen HE, Bergmann OJ, Boesen AM, Pedersen BB, Ellegaard J, Bastrup-Madsen P. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision]. *Ugeskr Laeger* 1989 Mar 27;151(13):816-21.

207) Johnsen HE, Bergmann OJ, Ellegaard J, Bastrup-Madsen P. Acute myeloid and lymphoblastic leukemia in adults. The course of the disease in 315 patients from one region, during a ten-year period. *Dan Med Bull* 1989 Apr;36(2):189-93.

208) Johnsen HE, Bergmann OJ, Boesen AM, Segel E, Kristensen JS, Bastrup-Madsen P, et al. [Chronic lymphatic leukemia. Prognosis and effects of treatment in 170 patients during the period 1976-1986]. *Ugeskr Laeger* 1988 Nov 7;150(45):2735-9.

209) Johnsen HE, Bergmann OJ, Bastrup-Madsen P. [Acute lymphoblastic leukemia in adults. Treatment results and prognosis]. *Ugeskr Laeger* 1987 Dec 14;149(51):3460-4.

210) Johnsen HE, Bergmann OJ, Madsen B, Kristensen JS, Brandsborg M, Ellegaard J, et al. [Acute myeloid leukemia. Effects of treatment and prognosis]. *Ugeskr Laeger* 1987 Jun 8;149(24):1598-603.

211) Knudsen TE, Larsen CS, Johnsen HE. A study of cyclic nucleotides as second messengers after interleukin 2 stimulation of human T lymphocytes. *Scand J Immunol* 1987 May;25(5):527-31.

212) Larsen CS, Knudsen TE, Johnsen HE. The role of calcium in stimulation of activated T lymphocytes with interleukin 2. *Scand J Immunol* 1986 Dec;24(6):689-97.

213) Hansen PW, Madsen M, Christiansen SE, Johnsen HE, Kissmeyer-Nielsen F. Cell-mediated PPD-specific cytotoxicity against human monocyte targets: evidence for restriction by class II HLA antigens. *Tissue Antigens* 1984 Mar;23(3):171-80.

214) Tauris P, Johnsen HE, Christiansen SE, Kissmeyer-Nielsen F. Plaque-forming cells in man. III. Generation of plaque-forming cells in allogeneic in vitro cultures of HLA-D/DR-incompatible B and T lymphocytes. *Scand J Immunol* 1984 May;19(5):419-24.

215) Christensen KD, Johnsen HE, Petersen CM. Cell-mediated immunity in seronegative spondylarthritis treated with levamisole in a double-blind placebo-controlled study. *Acta Pathol Microbiol Immunol Scand [C]* 1983 Dec;91(6):391-5.

216) Johnsen HE, Madsen M, Mossin J, Kristensen T. Influence of HLA-D/DR antigen disparity in CTL generation in vitro. *Tissue Antigens* 1983 Aug;22(2):142-50.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

- 217) Lanng NJ, Tauris P, Johnsen HE, Ellegaard J. The cellular immune response after splenectomy in humans. Impaired immunoglobulin synthesis in vitro. *Scand J Haematol* 1983 Jul;31(1):85-95.
- 218) Johnsen HE, Madsen M, Mossin J, Christiansen SE, Hansen PW. Activation of human alloreactive cytotoxic precursor T lymphocytes. *Hum Immunol* 1982 Aug;5(1):73-82.
- 219) Johnsen HE, Mossin J, Madsen M, Kristensen T, Kissmeyer-Nielsen F. Human B-blast specific target determinants in CML: a family study. *Tissue Antigens* 1982 Mar;19(3):222-9.
- 220) Madsen M, Johnsen HE, Kristensen T, Jorgensen F, Lamm LU, Kissmeyer-Nielsen F. Planned immunization of human volunteers with HLA-DR incompatible lymphocytes I. Serological aspects. *Tissue Antigens* 1982 Jul;20(1):33-46.
- 221) Ehlers N, Olsen T, Johnsen HE. Corneal graft rejection probably mediated by antibodies. *Acta Ophthalmol (Copenh)* 1981 Feb;59(1):119-25.
- 222) Johnsen HE. Lymphocyte subpopulations in man: induction of cytotoxic T lymphocytes in vitro by allogeneic B and T cells. *Tissue Antigens* 1981 Aug;18(2):108-24.
- 223) Johnsen HE. Lymphocyte subpopulations in man: T-cells with FcR for IgG in the allogeneic response in vitro. *Acta Pathol Microbiol Scand [C]* 1981 Aug;89(4):287-91.
- 224) Johnsen HE. Lymphocyte subpopulations in man: enhancement and inhibition in generation of cytotoxic T lymphocytes in vitro. *Tissue Antigens* 1981 Aug;18(2):125-35.
- 225) Kristensen T, Johnsen HE, Mossin J, Jorgensen F, Lamm LU, Kissmeyer-Nielsen F. Typing by cytotoxic lymphocytes. Genetics of HLA-non-A, B, C determinants - family studies. *Tissue Antigens* 1981 May;17(5):455-63.
- 1980-1978**
- 226) Bradley BA, Charmot D, Goulmy E, Johnsen HE, Kristensen T, Mawas C, et al. Histocompatibility typing by cell mediated lympholysis (CML): workshop II technical standardization. *Tissue Antigens* 1980 Jul;16(1):73-90.
- 227) Johnsen HE. Human B-blast specific target determinants in CML: a methodological study. *Tissue Antigens* 1980 Feb;15(2):189-98.
- 228) Johnsen HE. Human B-blast specific target determinants in CML: a panel study. *Tissue Antigens* 1980 Feb;15(2):199-209.
- 229) Johnsen HE, Madsen M. Lymphocyte subpopulations in man: characterization of in vivo-educated, alloreactive, cytotoxic lymphocytes. *Acta Pathol Microbiol Scand [C]* 1980 Jun;88(3):163-71.
- 230) Madsen M, Johnsen HE, Hansen PW, Christiansen SE. Isolation of human T and B lymphocytes by E-rosette gradient centrifugation. Characterization of the isolated subpopulations. *J Immunol Methods* 1980;33(4):323-36.
- 231) Johnsen HE, Madsen M, Kristensen T. Lymphocyte subpopulations in man: suppression of PWM-induced B-cell proliferation by infectious mononucleosis T cells. *Scand J Immunol* 1979;10(3):251-5.
- 232) Johnsen HE, Madsen M. Lymphocyte subpopulations in man: relationship between four subpopulations identified by membrane markers. *Scand J Immunol* 1979;9(5):419-27.
- 233) Johnsen HE, Madsen M. Lymphocyte subpopulations in man: B-cell stimulation induced by pokeweed mitogen and irradiated T cells. *Scand J Immunol* 1979;10(3):241-9.

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

- 234) Johnsen HE, Madsen M. Lymphocyte subpopulations in man: characterization of human killer cells against allogeneic targets sensitized with HLA antibodies. *Scand J Immunol* 1979;9(5):429-40.
- 235) Madsen M, Johnsen HE. A methodological study of E-rosette formation using AET-treated sheep red blood cells. *J Immunol Methods* 1979 May 10;27(1):61-74.
- 236) Madsen M, Johnsen HE, Kissmeyer-Nielsen F. HLA-DR typing of frozen B lymphocytes. *Transplant Proc* 1979 Jun;11(2):1321.
- 237) Madsen M, Johnsen HE, Kissmeyer-Nielsen F. Separation of human T and B lymphocytes using AET-treated sheep red blood cells. *Transplant Proc* 1979 Jun;11(2):1381-2.
- 238) Madsen M, Johnsen HE, Kissmeyer-Nielsen F. HLA-DR typing of frozen B lymphocytes. *Tissue Antigens* 1979 Feb;13(2):135-42.
- 239) Johnsen HE, Madsen M, Kristensen T, Kissmeyer-Nielsen F. Lymphocyte subpopulations in man. Expression of HLA-DR determinants on human T cells in infectious mononucleosis. *Acta Pathol Microbiol Scand [C]* 1978 Dec;86C(6):307-14.
- 240) Johnsen HE, Brostrphom K, Madsen M. Paroxysmal cold haemoglobinuria in children: 3 cases encountered within a period of 7 months. *Scand J Haematol* 1978 May;20(5):413-6.
- 241) Johnsen HE, Madsen M. Lymphocyte subpopulations in man: ox erythrocytes as indicators in the EA- and EAC-rosette tests: serological and technical aspects. *Scand J Immunol* 1978;8(3):247-56.
- 242) Johnsen HE, Madsen M. Lymphocyte subpopulations in man: no selective loss during isolation from defibrinated blood. *Scand J Immunol* 1978;8(3):239-45.

Non peer-reviewed publications

- 243) Kjeldsen MK and Johnsen HE. 2007. *Kræftstamceller - hvad er nu det for en størrelse*. 2007. *Lægen i midten*. 2, p. 12-13 (non peer-review)
- 244) Kjeldsen MK, Johnsen HE, Dahlgaard J and Dybkær K. 2007. *Kræftstamceller - på jagt efter ondets rod*. *Aktuel Naturvidenskab*. p. 23-25 Formidling › Tidsskriftartikel › (non peer-review)

CLINICAL INVESTIGATOR IN INTERNATIONAL CLINICAL TRIALS NOW PUBLISHED.

1. Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Ann E. Hunter, Lars Kjeldsen, John Yin, Brenda E.S. Gibson, Keith Wheatley, and Donald Milligan. 2013. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. *J Clin Oncol*.
2. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. 2011. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. *Lancet Oncol*. 12(11):1013-22.
3. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Yin J, McMullin M-F, Cahalin P, Craig J, Bowen D, Russell N; 2011. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. *Leukemia* 1–6

PUBLICATION LIST APRIL 2014– JOHNSEN HANS ERIK

4. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group. 2010. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood*. 22;116(3):354-65.
5. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol*. 2008 Feb;9(2):105-16.
6. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. *Lancet Oncol*. 2006 May;7(5):379-91.
7. Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wisløff F; Nordic Myeloma Study Group. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. *Br J Haematol*. 2004 Apr;125(2):149-55.
8. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, Bacigalupo A; European Group for Blood and Marrow Transplantation Working Party for Severe Aplastic Anemia. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. *Br J Haematol*. 2002 Dec;119(4):1075-82.